A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome

NCT07406932 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Antisynthetase Syndrome
Interstitial Lung Disease (ILD)

Interventions

DRUG: JAK Inhibitor
DRUG: Calcineurin Inhibitors (CNI)

Sponsor

China-Japan Friendship Hospital